Skip to main content
Fig. 4 | The Journal of Headache and Pain

Fig. 4

From: Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders

Fig. 4

Galcanezumab effects on migraine days per month in (A) all 46 patients, (B) 24 responders only, and (C) 19 non-responders. Differences in percentages of migraine days per month at baseline (before treatment) and in each of the 3 treatment months are shown in box-and-whisker plots (median [IQR]) combined with scatterplots of individual values. Note that the percentage of migraine days per month decreased significantly, although to a different extent, in all 3 groups

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us